this was definitely for a broader audience / but the net of it is, we are in restart mode and we are a biotech company in early clinical trials which means 3-4 years out for the market place for a drug most likely . therefore, our market cap of 250m is about right . still have the hurdles to get over from a financial standpoint, AMarex issue, and safety hold....